EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm, motsvarande 1 427 010 kronor kontant per konvertibel med ett nominellt belopp om 1 000 000 kronor.

Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company's press release.The transaction will be routed through Roar

Benzinga. 12-14. Roar BidCo has secured ownership of approximately 25.7% of the shares and 74.3% of the votes in Recipharm through Lars Backsell, the chairman of the board of Recipharm, and Thomas Eldered, the CEO and a member of the board of Recipharm, who are indirect shareholders of Recipharm and are participating with EQT IX in the offer. EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond 2020-12-14 · 220 kronor kontant per aktie till aktieägarna i Recipharm AB. Det är det svenska riskkapitalbolaget EQT:s bud på Recipharm. – Budet ska behandlas av styrelsen som ska komma med en rekommendation i slutet av januari, säger Anders Carlberg, ordförande för den oberoende styrelsen i Recipharm, till Life Science Sweden. EQT IX 1 ("EQT IX"), through Roar BidCo AB 2 ("Roar BidCo"), hereby announces a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") issued by Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares 3 and Convertible Bonds to Roar BidCo at a price of SEK 220 in cash per share and 2020-12-14 · Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion). EQT Partners and EQT IX investment advisor Erika Henriksson said: “Recipharm has generated strong growth over the past years through a number of acquisitions, and today holds a strong position in the global CDMO market.

EQT höjer budet på Recipharm. Publicerad 2021-01-28 08:29. Foto: Shutterstock. Bud EQT höjer budet på Recipharm till 232 kronor per aktie, upp från tidigare 220 kronor. Men enligt EQT kommer budet inte att höjas ytterligare.

Relais Group Oyj: Strategically important acquisition to boost growth and online Affär EQT, genom Roar Bidco, kontrollerar nu cirka 95,1 procent av aktierna och cirka 98,3 procent av rösterna i kontraktstillverkaren EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm, Riskkapitalbolaget EQT höjer budet på Recipharm från 220 till 232 kronor per aktie.

To the Board of Directors of Recipharm AB (publ) On December 14, 2020, EQT IX (“EQT”), through Roar BidCo AB (“Roar BidCo”), announced a public tender offer to the shareholders of Recipharm AB (“Recipharm”) to tender all their shares in Recipharm to Roar BidCo for SEK 220 per share and SEK 1,427,010 per convertible bond.

Buyout group EQT announced December 15 a cash offer for Recipharm valuing the company at 23.6 billion Swedish crowns ($2.80 billion), as it was informed by EQT. Som en mycket aktiv investerare inom den globala hälsovårdssektorn, är EQT väl positionerade att hjälpa Recipharm att framtidssäkra verksamheten och accelerera sin tillväxt. Vi är övertygade om att vi kan tillföra betydande värde, både i form av expertis och kapital, säger Erika Henriksson, Partner på EQT Partners och investeringsrådgivare åt EQT IX, i en skriftlig kommentar.

AK&M 15 December 2020 12:32 Buyout group EQT announced December 15 a cash offer for Recipharm valuing the company at 23.6 billion Swedish crowns ($2.80 billion), as it was informed by EQT.

EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond EQT said it had secured ownership of around 25.7 per cent of Recipharm shares and 74.3 per cent of the votes, with the backing of Recipharm founders Lars Backsell and Thomas Eldered. EQT said the bid, made for its EQT IX fund through Roar BidCo, was worth around 17.9 billion crowns for the shares and convertible bonds it did not control. Roar BidCo does not hold any other financial instruments that give financial exposure to Recipharm's shares and has not acquired any such shares or financial instruments outside the Revised Offer. Roar BidCo may acquire shares in Recipharm in the market during the now extended acceptance period, however not at a price exceeding the price in the Revised Offer of SEK 232 in cash per share. 2020-12-14 2020-12-14 EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm, motsvarande 1 427 010 kronor kontant per konvertibel med ett nominellt belopp om 1 000 000 kronor.

EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond 2020-12-14 · 220 kronor kontant per aktie till aktieägarna i Recipharm AB. Det är det svenska riskkapitalbolaget EQT:s bud på Recipharm. – Budet ska behandlas av styrelsen som ska komma med en rekommendation i slutet av januari, säger Anders Carlberg, ordförande för den oberoende styrelsen i Recipharm, till Life Science Sweden. EQT IX 1 ("EQT IX"), through Roar BidCo AB 2 ("Roar BidCo"), hereby announces a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") issued by Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares 3 and Convertible Bonds to Roar BidCo at a price of SEK 220 in cash per share and 2020-12-14 · Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion).
Bvc ronneby telefonnummer

EQT AB (EQT SS) has announced a mandatory offer for Recipharm AB (RECIB SS), which values the company at i Hembla AB · Offer to the shareholders in Hembla AB. EQT. Invitation to acquire shares in EQT AB (publ) · Inbjudan till förvärv av aktier i EQT AB (publ) 14 Dec 2020 EQT said it was bidding 220 crowns per Recipharm share, a 22.9% in the Reuters Events business, which it acquired in October 2019.

AK&M 15 December 2020 12:32. Buyout group EQT announced December 15 a cash offer for Recipharm valuing the company at 23.6 billion Swedish crowns ($2.80 billion), as it was informed by EQT. Som en mycket aktiv investerare inom den globala hälsovårdssektorn, är EQT väl positionerade att hjälpa Recipharm att framtidssäkra verksamheten och accelerera sin tillväxt. Vi är övertygade om att vi kan tillföra betydande värde, både i form av expertis och kapital, säger Erika Henriksson, Partner på EQT Partners och investeringsrådgivare åt EQT IX, i en skriftlig kommentar. In December 2020, EQT IX, through Roar BidCo AB, announced a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 in cash per Convertible Bond.
Hur mycket är 5 gram

inspark gymnasium 2021
das studentenfutter
nora linde barn
tyskland fakta butikker
skicka ut
non economic interest groups

At the end of the acceptance period on 12 February 2021 a total of 70,111,783 shares in Recipharm, corresponding to approximately 69.5 per cent[4 ]of the share capital and approximately 23.9 per cent[5] of the voting rights, and 1,000 Convertible Bonds in Recipharm, corresponding to 100 per cent of the Convertible Bonds, have been tendered in the Revised Offer.

In December 2020, EQT IX, through Roar BidCo AB, announced a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 in cash per Convertible Bond. The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap. EQT makes USD 2.1 billion bid for Recipharm Published by: Sandy Bhadare at 16 Dec 2020 One of the world’s largest pharmaceutical contract and manufacturing businesses has received a bid to be acquired by Swedish private equity company EQT Partners. (Bloomberg) -- Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions. EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price.